{
}
Sanofi's CEO, Paul Hudson, acknowledged "difficult discussions" with the French government regarding the sale of its OTC subsidiary, Opella, which markets Doliprane. The negotiations, under significant political pressure, resulted in commitments to maintain production in France and preserve jobs at local sites for at least five years. The French government will have a minor stake in Opella, ensuring governance without deterring foreign investment.
Paris has imposed strict penalties on Opella, a paracetamol manufacturer, to ensure it maintains production and jobs in France following its acquisition by US firm CD&R. The agreement includes a €40 million penalty for halting production at key factories and a €100 million fine for not sourcing paracetamol ingredients from a future French facility. The French government will also invest up to €150 million in Opella to secure oversight of its operations.
The French government has secured strong guarantees in the sale of a 50% stake in Opella, producer of Doliprane, to American investment fund CD & R, which aims to enhance growth. The agreement includes a €70 million investment in France, job protection, and penalties for production stoppages. Sanofi retains a 48% stake, ensuring continued involvement in Opella's operations.
Paris has approved a €15 billion sale of paracetamol manufacturer Opella to a US fund, securing guarantees for its continued operation and development in France. Despite political concerns over potential job losses and supply chain impacts, the government believes foreign investment is crucial for enhancing the country's pharmaceutical sector. An investment screening will follow the agreement, which involves Sanofi and the American buyer.
The French government has reached a tripartite agreement with Sanofi and the American investment fund CD&R for the sale of the Opella subsidiary, which markets Doliprane. The deal includes strong guarantees for maintaining production in France, with a commitment to produce 250 million boxes annually and significant penalties for non-compliance. CD&R will invest €70 million over five years, while the French state will hold a minority stake through Bpifrance to ensure governance and adherence to the agreed conditions.
Sanofi is in exclusive negotiations to sell a majority stake in its consumer healthcare subsidiary Opella, which produces Doliprane, to the American investment fund CD & R for over 15 billion euros. This move raises concerns about potential relocation of production, despite government efforts to reduce drug import dependence. French officials are urging commitments to maintain Opella's operations in France amid fears of losing the iconic Doliprane brand.
Sanofi is negotiating to sell a 50% stake in its consumer healthcare division, Opella, to U.S. private equity firm CD&R for approximately 15.5 billion euros. The French government is closely monitoring the deal, emphasizing the need for economic commitments to maintain operations and decision-making in France.
Marc Ferracci
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Sanofi's Doliprane sale faces tough negotiations with French government
United States Dollar
Bpifrance
Sanofi
CD&R
USA
FRA
Marc Ferracci
Paul Hudson
Antoine Armand
Show more
11:47 22.10.2024
France imposes penalties on Opella to retain jobs and production after takeover
13:28 21.10.2024
French government secures guarantees in sale of Doliprane to US fund
Euro
Rexel S.A.
SPIE SA
Seqens
Sanofi
CD & R
USA
CHN
FRA
Marc Ferracci
Nicolas Dufourcq
Paul Hudson
Antoine Armand
Show more
11:05 21.10.2024
France approves 15 billion euro sale of paracetamol maker to US fund
22:00 20.10.2024
French government secures stake in Sanofi subsidiary for Doliprane production guarantees
Euro
CD&R Blossom Holdings LP
Sanofi
FRA
USA
Marc Ferracci
Antoine Armand
Nicolas Dufourcq
Laurent Saint-Martin
Show more
20:43 20.10.2024
Sanofi in talks to sell Doliprane brand to American investment fund
11:57 11.10.2024
Sanofi in talks to sell 50 percent stake in Opella to CD&R
Euro
Les Echos A.C
Le Monde 3D Sàrl
Clayton Dubilier & Rice (CD&R)
Sanofi
PAI Partners SAS
FRA
USA
Marc Ferracci
Antoine Armand
Show more
09:00 11.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Stock Market Updates
Retail and Consumer Goods
Supply Chain Management
Industry Mergers & Acquisitions
Government Economic Policies
Fintech Startups
Private Equity Deals
AI Applications
Venture Capital Investments
AI Innovations
Funding Rounds & Investments
CEO Changes
Economic Indicators
Emerging Startups
Corporate Social Responsibility
Real Estate Investments
Countries:
Companies:
Apple Inc.
OLA ELECTRIC MOBILITY LTD
Grab2Go AS
Google Inc.
EFG Hermes Egypt
Delhivery Limited
Ecom Express Ltd.
Scripbox.COM India Ltd.
NVIDIA Corp
Amazon.com, Inc.
OpenAI ERC USD
FTSE NASDAQ Dubai UAE 20 Index
Broadcom Inc.
The Goldman Sachs Group, Inc.
Microsoft Corp
JPMorgan Chase & Co.
Morgan Stanley
XIAOMI-W
Li Auto Inc.
Tesla, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
Pakistani Rupee
Egyptian Pound
South Korean Won
United Arab Emirates Dirham
Qatari Riyal
Indonesian Rupiah
Brazilian Real
Saudi Riyal
Vietnamese Đồng
Hong Kong Dollar
Offshore Chinese Yuan
Canadian Dollar
People: